Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy.
We report 2 sisters with hyper-IgE syndrome treated with daily suppressive dosages of linezolid (LZD) who developed LZD-resistant Staphylococcus aureus carrying the G2576T mutation in the 23S rRNA gene. Molecular typing suggested transmission of the resistant strain from one sister to the other. LZD-susceptible S. aureus was isolated 2 months after LZD discontinuation. LZD-resistant S. aureus remains rare but may occur while receiving suppressive therapy.
Roberts
Susanne M
SM
Department of Laboratory Medicine, Clinical Center, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892, USA.
Freeman
Alexandra F
AF
Harrington
Susan M
SM
Holland
Steven M
SM
Murray
Patrick R
PR
Zelazny
Adrian M
AM
D000081:Acetamides / Q000008:administration & dosage*; D000293:Adolescent; D002648:Child; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007589:Job Syndrome / Q000175:diagnosis / Q000276:immunology*; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000008:administration & dosage*; D018570:Risk Assessment; D035781:Siblings; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D016896:Treatment Outcome
D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid